At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Smartphone-based AI skin lesion analysis (NuvanaDx platform). (diagnostic test)
- How long the study runs
- Study runs about 3 months (dates as stated)
- About the drug or intervention
- Smartphone-based AI skin lesion analysis (NuvanaDx platform). — diagnostic test: Smartphone-based AI skin lesion analysis (NuvanaDx platform).
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is looking at whether artificial intelligence (AI) — computer software — can help find melanoma, a type of skin cancer, early. It is for adults who have a skin change that doctors think might be cancer. The sponsor (the organisation running the study) is Nuvana Healthcare LTD.
Who can take part
- Adults aged 18 or over
- People with a skin change, such as a spot or lump, that doctors think might be cancer
- People who can give informed consent (agree to take part after being told what the study involves)
Who may not be able to
- People who cannot give informed consent
- People whose skin pictures are too poor in quality for the AI software to check
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about the number of visits, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Months and over
- Who
- All
- Number of participants
- 100
- Started
- 2025-10-01
- Last checked
- 2025-09
Plain English Summary
What is this study?
- • Testing a new treatment for skin cancer melanoma
- • Clinical study - 100 participants
- • This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging
Who can take part?
- • Ages 18 Months and over
- • Diagnosed with skin cancer melanoma
Where?
- • London - Nuvana Healthcare Ltd
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
More detail
The study will collect retrospective and prospective anonymized skin lesion images and metadata to validate the AI algorithm against dermatology-confirmed diagnoses. The aim is to determine sensitivity, specificity, and predictive value of the AI tool across diverse populations and skin tones. The study will also assess user experience, accessibility, and integration into clinical care pathways.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Months and over
- Who can join: All genders
What the study is looking for
- ✓Adults (≥18 years) presenting with skin lesions suspicious for cancer.
- ✓Ability to provide agreement to take part.
Who cannot take part
- ✗Inability to provide agreement to take part.
- ✗Poor-quality images unsuitable for AI analysis.
See the full criteria
Where Is This Study? (1 UK site)
Nuvana Healthcare Ltd
London, United Kingdom
How to Get in Touch
Sushma Saxena, Director, Nuvana Healthcare Ltd
Sponsor contactCONTACT